<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03480529</url>
  </required_header>
  <id_info>
    <org_study_id>CIC1421-18-05</org_study_id>
    <nct_id>NCT03480529</nct_id>
  </id_info>
  <brief_title>Monitoring the IMmUological TOXicity of Drugs</brief_title>
  <acronym>MIMUTOX</acronym>
  <official_title>Monitoring the IMmUological TOXicity of Drugs</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Groupe Hospitalier Pitie-Salpetriere</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Groupe Hospitalier Pitie-Salpetriere</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Several drugs and chemotherapies seem to have an impact on the immunological system. This
      study investigates reports of immunological toxicities, including the International
      classification of disease ICD-10 codes M05, M32, I78 for treatments in the World Health
      Organization (WHO) global Individual Case Safety Report (ICSR) database (VigiBase).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Several drugs and chemotherapies seem to have an impact on the immunological system and are
      responsible of a wide range of rare immunological side effects. Those are poorly described,
      due to the modification of the pharmacopeia, and the recent recognition of several of these
      adverse events. This study investigates the main characteristics of patients affected by rare
      immunological side effects (of which systemic lupus, immune arthritis, rheumatoid arthritis,
      Hepatitis, capillary leak syndrome) imputed to drugs. A causality assessment according to the
      WHO-UMC (World Health Organization - Uppsala Monitoring Center) is systematically applied.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 1, 2018</start_date>
  <completion_date type="Actual">March 10, 2018</completion_date>
  <primary_completion_date type="Actual">March 10, 2018</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <target_duration>1 Day</target_duration>
  <primary_outcome>
    <measure>Arthritis, hepatitis, and lupus induced toxicity of Immune Checkpoint inhibitors (ICI) Identification and report of cases of arthritis or lupus associated with ICIs. The research includes the report with MedDRA terms:</measure>
    <time_frame>Case reported in the World Health Organization (WHO) database of individual safety case reports to 02/01/2018</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Causality assessment of reported arthritis, hepatitis, or lupus events according to the WHO system</measure>
    <time_frame>Case reported in the World Health Organization (WHO) database of individual safety case reports to 02/01/2018</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of the type of arthritis or lupus or hepatitis or capillary leak syndrom depending on the category of drug</measure>
    <time_frame>Case reported in the World Health Organization (WHO) database of individual safety case reports to 02/01/2018</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of the other immune related adverse events concomitant to the arthritis or lupus or hepatitis or capillary leak syndrom induced by drugs</measure>
    <time_frame>Case reported in the World Health Organization (WHO) database of individual safety case reports to 02/01/2018</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of the duration of treatment when the toxicity happens (role of cumulative dose)</measure>
    <time_frame>Case reported in the World Health Organization (WHO) database of individual safety case reports to 02/01/2018</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of the drug-drug interactions associated with adverse events</measure>
    <time_frame>Case reported in the World Health Organization (WHO) database of individual safety case reports to 02/01/2018</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of the pathologies (cancer) for which the incriminated drugs have been prescribed</measure>
    <time_frame>Case reported in the World Health Organization (WHO) database of individual safety case reports to 02/01/2018</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of the population of patients having a arthritis or lupus or hepatitis or CLS adverse event</measure>
    <time_frame>Case reported in the World Health Organization (WHO) database of individual safety case reports to 02/01/2018</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">662</enrollment>
  <condition>Arthritis</condition>
  <condition>Systemic Lupus Erythematosus</condition>
  <condition>Rheumatoid Arthritis</condition>
  <condition>Capillary Leak Syndrome</condition>
  <condition>Hepatitis</condition>
  <arm_group>
    <arm_group_label>Arthritis or lupus or CLS induced by a drug</arm_group_label>
    <description>Case reported in the World Health Organization (WHO) of arthritis or lupus, or Hepatitis, or capillary leak syndrome of patient treated by a drug, with a chronology compatible with the drug toxicity</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>drug inducing arthritis, lupus, hepatitis, or capillary leak syndrom</intervention_name>
    <description>Drugs susceptible to induce arthritis, lupus, hepatitis, or capillary leak syndrom</description>
    <arm_group_label>Arthritis or lupus or CLS induced by a drug</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients treated with a drug that could be reported in the WHO's pharmacovigilance database
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Case reported in the WHO's pharmacovigilance database till 02/01/2018

          -  Adverse event reported were including the MedDRA terms for immune arthritis, systemic
             lupus erythematosus, hepatitis, rheumatoid arthritis and capillary leak syndrome.

        Exclusion Criteria:

          -  Chronology not compatible between the drug and the toxicity
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>AP-HP, Pitié-Salpêtrière Hospital, Department of Pharmacology, CIC-1421, Pharmacovigilance Unit, INSERM.</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rhumatology department, CHU Strasbourg, Hautepierre hospital</name>
      <address>
        <city>Strasbourg</city>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <results_reference>
    <citation>Arnaud L, Lebrun-Vignes B, Salem JE. Checkpoint inhibitor-associated immune arthritis. Ann Rheum Dis. 2019 Jul;78(7):e68. doi: 10.1136/annrheumdis-2018-213470. Epub 2018 May 3.</citation>
    <PMID>29724725</PMID>
  </results_reference>
  <results_reference>
    <citation>Mertz P, Lebrun-Vignes B, Salem JE, Arnaud L. Characterizing drug-induced capillary leak syndromes using the World Health Organization VigiBase. J Allergy Clin Immunol. 2019 Jan;143(1):433-436. doi: 10.1016/j.jaci.2018.09.001. Epub 2018 Sep 20.</citation>
    <PMID>30244023</PMID>
  </results_reference>
  <results_reference>
    <citation>Arnaud L, Mertz P, Gavand PE, Martin T, Chasset F, Tebacher-Alt M, Lambert A, Muller C, Sibilia J, Lebrun-Vignes B, Salem JE. Drug-induced systemic lupus: revisiting the ever-changing spectrum of the disease using the WHO pharmacovigilance database. Ann Rheum Dis. 2019 Apr;78(4):504-508. doi: 10.1136/annrheumdis-2018-214598. Epub 2019 Feb 4.</citation>
    <PMID>30793701</PMID>
  </results_reference>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>March 21, 2018</study_first_submitted>
  <study_first_submitted_qc>March 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 29, 2018</study_first_posted>
  <last_update_submitted>September 2, 2019</last_update_submitted>
  <last_update_submitted_qc>September 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Groupe Hospitalier Pitie-Salpetriere</investigator_affiliation>
    <investigator_full_name>Joe Elie Salem</investigator_full_name>
    <investigator_title>MD,PhD</investigator_title>
  </responsible_party>
  <keyword>adverse event</keyword>
  <keyword>arthritis</keyword>
  <keyword>Systemic Lupus Erythematosus</keyword>
  <keyword>Capillary Leak Syndrome</keyword>
  <keyword>Hepatitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Capillary Leak Syndrome</mesh_term>
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

